AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
2.670
-0.040 (-1.48%)
At close: Nov 20, 2024, 4:00 PM
2.630
-0.040 (-1.50%)
Pre-market: Nov 21, 2024, 4:59 AM EST

AbCellera Biologics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018
Period Ending
Nov '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018
Market Capitalization
7891,6572,8984,02710,832-
Upgrade
Market Cap Growth
-42.44%-42.83%-28.02%-62.83%--
Upgrade
Enterprise Value
2179522,1063,30510,829-
Upgrade
Last Close Price
2.675.7110.1314.3040.24-
Upgrade
PE Ratio
--18.2826.24127.29-
Upgrade
Forward PE
---51.81--
Upgrade
PS Ratio
23.7443.575.9710.7346.46-
Upgrade
PB Ratio
0.731.442.353.9313.04-
Upgrade
P/TBV Ratio
0.781.682.754.8515.84-
Upgrade
P/FCF Ratio
--14.0221.63832.15-
Upgrade
P/OCF Ratio
--10.4516.46477.40-
Upgrade
EV/Sales Ratio
6.5825.034.348.8146.45-
Upgrade
EV/EBITDA Ratio
--8.6215.1067.32-
Upgrade
EV/EBIT Ratio
--9.3616.1769.40-
Upgrade
EV/FCF Ratio
--10.1917.76831.92-
Upgrade
Debt / Equity Ratio
0.070.070.070.040.010.67
Upgrade
Debt / EBITDA Ratio
--0.320.180.03-
Upgrade
Debt / FCF Ratio
--0.400.220.34-
Upgrade
Asset Turnover
0.020.030.340.320.450.52
Upgrade
Inventory Turnover
-133.12108.8169.8671.97-
Upgrade
Quick Ratio
8.886.938.377.447.811.51
Upgrade
Current Ratio
9.347.338.677.707.861.60
Upgrade
Return on Equity (ROE)
-15.55%-12.27%14.03%16.53%28.29%-20.23%
Upgrade
Return on Assets (ROA)
-13.26%-9.79%9.83%10.99%18.95%-11.44%
Upgrade
Return on Capital (ROIC)
-15.96%-11.65%11.81%13.44%22.89%-15.98%
Upgrade
Earnings Yield
-22.29%-8.84%5.47%3.81%1.10%-
Upgrade
FCF Yield
-25.03%-7.29%7.13%4.62%0.12%-
Upgrade
Buyback Yield / Dilution
-1.70%8.15%1.09%-20.96%-73.88%11.68%
Upgrade
Total Shareholder Return
-1.70%8.15%1.09%-20.96%-73.88%11.68%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.